Allarity Therapeutics, Inc. (ALLR)
$
0.91
-0.05 (-5.49%)
Key metrics
Financial statements
Free cash flow per share
-16.9096
Market cap
13.7 Million
Price to sales ratio
0
Debt to equity
0.0730
Current ratio
2.6600
Income quality
0.7926
Average inventory
0
ROE
-1.5149
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncology therapeutics through its innovative drug response predictor technology, which generates drug-specific companion diagnostics. This approach is evident in its promising drug candidates, including Stenoparib, a poly-ADP-ribose polymerase inhibitor currently undergoing Phase 2 clinical trials for ovarian cancer, and Dovitinib, a pan-tyrosine kinase inhibitor designed for the treatment of renal cell carcinoma. Additionally, IXEMPRA serves as a microtubule inhibitor aimed at treating metastatic breast cancer. The company is also advancing LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 trials for metastatic breast cancer, along with 2X-111, a liposomal formulation of doxorubicin, currently in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company incurred an income tax expense of -$381,000.00 indicating its tax obligations. The company's stock is identified with the symbol 'ALLR' in the market, and its net income ratio is 0.00 reflecting the company's profitability margin. The operating expenses amount to $17,538,000.00 encompassing various operational costs incurred, and the company reported depreciation and amortization expenses of -$1,692,000.00 highlighting the wear and tear of its assets. In the current market environment, the stock is affordable at $1.05 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 460,858.00 indicating lower market activity, which may appeal to certain investment strategies. With a market capitalization of $13,723,918.00 the company is classified as a small-cap player and plays a significant role in the Biotechnology industry, contributing notably to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within the competitive biopharmaceutical landscape. The combination of its strategic drug development and financial metrics presents a comprehensive view of Allarity Therapeutics' position and prospects in the evolving oncology market.
Is Allarity Therapeutics, Inc. (ALLR) a good investment?
Investing in Allarity Therapeutics, Inc. (ALLR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Allarity Therapeutics, Inc. (ALLR)'s stock forecast?
Analysts predict Allarity Therapeutics, Inc. stock to fluctuate between $0.61 (low) and $6 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Allarity Therapeutics, Inc.'s market capitalization?
As of 2025-08-19, Allarity Therapeutics, Inc.'s market cap is $13,723,918, based on 15,079,572 outstanding shares.
How does Allarity Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Allarity Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Allarity Therapeutics, Inc. (ALLR) stock?
To buy Allarity Therapeutics, Inc. (ALLR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALLR. Place an order (Market, Limit, etc.).
What is the best time to invest in Allarity Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Allarity Therapeutics, Inc. stock ever split?
Allarity Therapeutics, Inc.'s last stock split was 1:30 on 2024-09-11.
How did Allarity Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$15.56 | Growth: 150,944.20%.
Where can I find Allarity Therapeutics, Inc.'s investor relations reports?
Visit https://www.allarity.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Allarity Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Allarity Therapeutics, Inc. stock?
All-time high: $15,288,000 (2021-12-21) | All-time low: $0.61 (2025-04-09).
What are the key trends affecting Allarity Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP ® companion diagnostic - Secured new service contract with EU biotech for Allarity Medical Laboratory TARPON SPRINGS, Fla., August 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today reported financial results and provided an update on operational highlights for the second quarter ended June 30, 2025.
globenewswire.com
TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor today announced that the second patient has been dosed in its new Phase 2 clinical trial protocol evaluating stenoparib in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer.
globenewswire.com
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company's Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity's development over the past two years.
globenewswire.com
- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months - Initiated utilization of share repurchase program - Cash and restricted cash balance of approximately $27 million at end of Q1 2025, reinforcing financial stability
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity Therapeutics, Inc.") (NASDAQ:ALLR) concerning possible violations of federal securities laws. On July 22, 2024, Allarity filed a current report on Form 8-K with the SEC.
prnewswire.com
LOS ANGELES , March 19, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ: ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
prnewswire.com
LOS ANGELES , March 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ: ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
globenewswire.com
Boston (March 13, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced that it has reached a final settlement with the U.S. Securities and Exchange Commission (SEC) relating to the previously disclosed investigation regarding the Company's past disclosures concerning its interactions with the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (“NDA”) for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021. This final settlement confirms the settlement in principle announced by the Company on January 30, 2025.
See all news
